54.00
+1.75
(3.35%)
May 23 - Close
LON real-time data - Disclaimer
Currency in GBX unless noted
| Range | 46.97 - 54.00 |
| 52 week | 39.00 - 130.00 |
| Open | 48.00 |
| Vol. | 109,527.00 |
| Mkt cap | 24.91M* |
| P/E | - |
| Div/yield | - |
| EPS | -0.34* |
| Shares | 46.13M |
| Beta | - |
| Inst. own | - |
| *GBP |
Events
May 15, 2013
SkyePharma PLC Annual General Meeting
Mar 21, 2013
Full Year 2012 SkyePharma PLC Earnings Presentation
Mar 21, 2013
Full Year 2012 SkyePharma PLC Earnings Release
|
|
Key stats and ratios
| Q4 (Dec '12) | 2012 | |
| Net profit margin | -26.58% | -21.24% |
| Operating margin | -5.32% | 3.41% |
| EBITD margin | - | 30.46% |
| Return on average assets | -23.55% | -15.27% |
| Return on average equity | - | - |
| Employees | 85 | - |
| Carbon Disclosure Rating | - | - |
Address
46-48 Grosvenor Gardens
LONDON, ENG SW1W 0EB
United Kingdom - Map
+44-20-78810524 (Phone)
+44-20-78811199 (Fax)
LONDON, ENG SW1W 0EB
United Kingdom - Map
+44-20-78810524 (Phone)
+44-20-78811199 (Fax)
Website links
External links
Analyst Estimates - BusinessWeek
Options - MarketWatch
Research Reports - Reuters
Director Dealings - Yahoo Finance
Discussion Group - Google Finance
Advertisement
Description
SkyePharma PLC is a speciality drug delivery company developing oral and inhalation products. The principal activities of the Company included the research and development, manufacture and sale of prescription pharmaceutical products. The Company is engaged in the development and manufacture of pharmaceutical products based on information used internally by management to assess the performance of, and allocate resources to the business. The Company�s Geomatrix and Geoclock technologies enable controlled- or timed-release versions of immediate-release products to be developed providing advantages to both partner companies and patients. There are 12 approved products in the areas of oral, inhalation and topical delivery, which incorporate the Company�s technologies. The Company�s subsidiaries include SkyePharma Production SAS, SkyePharma (Jersey) Limited, Jago Holding AG, Jagotec AG, SkyePharma AG, SkyePharma Holding AG and SkyePharma Holding Inc.
Officers and directors
| Peter Grant | Chief Executive Officer, Executive Director | |
| John Murphy | General Counsel, Company Secretary | |
| Frank C. Condella Jr. | Non-Executive Independent Chairman of the Board | |
| Alan Bray | Senior Non-Executive Independent Director | |
| Jean-Charles Tschudin | Non-Executive Independent Director | |
| Thomas Werner | Non-Executive Independent Director |